CD4 and myeloid sarcoma: Our study was too small to provide a statistical correlate for lack of disease progression (typically defined by the absence both of relapsing events and the appearance of new MRI lesions during therapy), with specific biomarkers which could be identified early in the treatment regimen, however, the results of our experiments suggest that IM IFN-β-1a's efficacy in reducing the number of exacerbation events in MS may involve modulation of the number of IL-12 and IL-23 receptors on CD4+ T-cells.